Release – Comstock Mining Launches Geophysical Surveys of the Southern Comstock District

 

Comstock Mining Launches Geophysical Surveys of the Southern Comstock District, Dayton Resource Area and Spring Valley Exploration Targets

 

Virginia City, NV (September 22, 2020) Comstock Mining Inc. (the “Company”) (NYSE American: LODE) announced today that Geotech Ltd. (“Geotech”) of Aurora, Canada, began conducting the previously announced airborne geophysical surveys last weekend, including the Dayton resource area, adjacent to Silver City, NV and the contiguous Spring Valley exploration targets all the way to Hwy 50.

Geotech launched its proprietary Versatile Time-Domain Electromagnetic (“VTEM”) geophysical system on Saturday, September 19, 2020, once visibility improved as smoke from the California fires cleared, and plans to complete the survey, by the end of September. The Company expects preliminary scans becoming available by mid-October, and extensive three-dimensional interpreted results later in the fourth quarter.

The results will greatly increase the Company’s understanding of the Dayton resource area and Spring Valley resource expansion potential, along with the Company’s other exploration targets in Lyon County.

Mr. Corrado De Gasperis, Executive Chairman and CEO stated, “Geotech’s proprietary surveys will provide invaluable data, to both corroborate and expand our knowledge of the potential mineralization, in the safest, least disruptive manner, and at depths not previously explored, enabling us to, among other things, refine and finalize a most effective and efficient exploration and development drill program.”

The entire press release can be read HERE

 

Contact information

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com

Comstock Mining Inc.
1200 American Flat Rd
PO Box 1118
Virginia City, NV 89440
http://www.comstockmining.com

Zach Spencer
Director of External Relations
Tel (775) 847-5272 ext.151
questions@comstockmining.com

Forty-Year Tax History vs. Current Campaign Promises

 

A Deep Dive into Candidate Biden’s Tax Proposals

 

Democrat Presidential nominee Joe Biden has proposed a number of changes to the tax code, including substantial reversals of reductions under the Tax Cuts and Jobs Act of 2017. Among the key proposals, Biden has included increasing the top marginal income tax rate to 39.6% from a current 37%, taxing capital gains at ordinary income tax rates, up from a top rate of 23.8% today, for those earning over $1 million, elimination of stepped-up basis for inherited assets with capital gains, applying the 12.4% Social Security tax on wages above $400,000 (currently the limit is $137,700, although the wage limit increases annually), and raising the corporate income tax to 28% from 21%. We would note that under the 2017 Act, nearly all the individual and estate tax rollbacks were to expire after 2025, although most of the corporate tax reductions were to be permanent.

On a historical basis, Biden’s tax proposals would be the fifth-largest tax increase, as a percent of GDP, since 1940, based on figures from the Treasury Department. Notably, the four larger tax hikes-during 1942, 1941, 1968, and 1951-all occurred during periods when the country was financing wars. Biden’s proposals would increase federal revenue as a percentage of GDP to a peak of 19.3% in 2027 and 18.9% in 2030 versus 17.8% under current law. This would bring the U.S. back up to the high point of revenue collection levels seen from 1998 to 2000 when the level peaked at 20% in 2000.

While Biden promises not to increase taxes on those earning less than $400,000, his tax proposals fall far short of his announced spending plan. Various organizations estimate Biden’s tax proposals would raise between $3.4 trillion to $3.7 trillion over the 2021-2030 time frame. But Biden’s announced spending plans are in excess of $6 trillion over the same period. As usual, the deficit would have to be financed either through additional tax increases, reductions in other federal spending, or increased government debt.

Ultimately, however, how do tax changes actually impact tax-paying individuals? Since 1980, there have been 60 major tax reforms enacted at the federal level, according to the Tax Policy Center. Over that time frame, Republicans controlled the White House for 24 years and Democrats for 16. If we look at data from 1980-2017 (the most recent data released by the IRS), we can see some interesting trends. Just looking at the top 1% of earners (and note due to changes in IRS definitions and methodologies, the historical numbers are not strictly comparable), the percent of Adjusted Gross Income (AGI) earned by the top 1% went from a low of 8.3% in 1981 to as high as 22.9% in 2007 to 21.0% in 2017. The percent of income tax paid by the top 1% rose from a low of 17.58% in 1981 to a high of 39.81% in 2007 to 38.47% in 2017. The average tax rate of the top 1% was 34.47% in 1980, hit a low of 22.46% in 2007, and was 26.76% in 2017. If we expand the analysis to the top 5% of income earners, AGI share was a low of 20.78% in 1981, hit a high of 37.39% in 2007, and was 36.53% in 2017. The group’s percent of federal taxes paid rose from a low of 35.06% in 1981 to a high of 59.9% in 2007 and was 59.14% in 2017. The average tax rate rose from 26.86% in 1980 to a low of 20.46% in 1990 to 23.7% in 2017. It will be interesting to see how these percentages changed as a result of the 2017 Act.

Of more importance may be Biden’s proposal to raise corporate income tax rates. Currently, the U.S. has the 84th highest combined statutory corporate income tax rate at 25.9%. Raising the corporate tax rate to 28% would result in a combined rate of 32.9%, raising the U.S. to the 20th highest corporate tax rate worldwide and well above the G7 average of 28% and the OCED average of 26.4%. The substantially higher corporate tax rate may put U.S. corporations at a competitive disadvantage. While increased corporate tax rates are not a direct tax increase on individuals, most economists agree the corporate tax burden is shared in some combination by shareholders, owners of capital, and workers, according to the Committee for a Responsible Budget, so individuals would see some type of indirect tax increase, although the size of the increase is debatable.

 

Suggested Reading:

JOLTS Report Suggests More Risk-Taking

Think You Know Who Will Win the Next Election? Want to Bet?

Virtual Conferences are Suddenly Mainstream

 

Each event in our popular Virtual Road Shows Series has a maximum capacity of 100 online investors. To take part, listen to and perhaps get your questions answered, see which virtual investor meeting intrigues you here.

 

Sources:

https://www.kiplinger.com/slideshow/taxes/t055-s001-2020-election-joe-biden-s-tax-plans/index.html

http://www.crfb.org/blogs/would-joe-biden-significantly-raise-taxes-middle-class-americans

http://www.crfb.org/sites/default/files/CRFB%20USBW%20Biden%20Tax%20Plan%20Analysis_FINAL%20DRAFT_07302020.pdf

https://taxfoundation.org/joe-biden-tax-increases-historical-context/

https://www.wsj.com/articles/where-trump-and-biden-stand-on-tax-policy-11600335001

https://www.taxpolicycenter.org/publications/analysis-former-vice-president-bidens-tax-proposals/full

https://www.taxpolicycenter.org/laws-proposals/major-enacted-tax-legislation-1980-1989

 

Photo Credit:  www.cafecredit.com

Industry Report – Metals and Mining Insights from the Precious Metals Summit

Monday, September 21, 2020

Minerals Industry Report

Insights from the Precious Metals Summit

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Precious Metals Summit goes virtual without missing a beat. The Precious Metals Summit went virtual this year and was held September 15-17. A diverse mix of business models including royalty companies, explorers, developers, and producers encompassed a broad range of precious and base metals. Jurisdiction attractiveness was a major point of differentiation highlighted in most presentations and panel discussions highlighted the importance for investors, during a precious metals bull market, to gauge the quality of managements since they are key to successful project identification and execution. A presentation by Stephen Moore, an advisor to President Trump, was interesting partly due to his veering from precious metals to make bullish comments on uranium and the potential for President Trump to issue an executive order declaring uranium a strategic resource for the United States. A panel featuring prominent buy-siders offered interesting insights ranging from their formulation of commodity price decks to what they look for in company presentations.
  • Resurgence of exploration activity. With rising metals prices, increased exploration activity is evident, not just in the number of new exploration projects and the resurrection of some projects that might have been unprofitable at lower prices, but also increasing budgets for greenfield and brownfield exploration across the sector. The financing environment has improved markedly versus a year ago and generalist investors have returned to the sector.
  • Resumption of M&A? A buyside panel highlighted that COVID-19 has made deal consummation difficult given that management teams are not as able to physically conduct site visits and due diligence meetings. As a result, M&A activity driven by acquirers’ needs to replenish reserves and/or achieve scale could accelerate once travel and physical interaction are less limited. More virtual discussions are likely taking place than meet the eye and, in some respects, the current environment may provide an opportunity for those able to make decisions without the usual protocols.
  • Metals outlook remains constructive. While the equities of major mining companies were the first to benefit from rising prices, interest has filtered down to the junior mining universe. While the conference offered many views on the trajectory of precious metals prices, we believe the outlook remains constructive. Interest in metals linked to electrification and clean energy continues to build and there was plenty of discussion around copper, nickel, and palladium as beneficiaries of these themes.

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.


IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.
The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.
Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis.
Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.”
FINRA licenses 7, 24, 63, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of
transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS
% OF SECURITIES COVERED
% IB CLIENTS
Outperform: potential return is >15% above the current price
88%
41%
Market Perform: potential return is -15% to 15% of the current price
12%
5%
Underperform: potential return is >15% below the current price
0%
0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same. Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
225 NE Mizner Blvd. Suite 150
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 11705
Metals & Mining | September 21, 2020

Onconova therapeutics ontx cdk4-6 program advances into clinic in china

Monday, September 21, 2020

Onconova Therapeutics Inc. (ONTX)

CDK4/6 Program Advances into Clinic in China

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Trial initiation in China by research partner Hanx. Onconova announced the commencement of trial of its CDK4/6 and ARK5 inhibitor ON 123300 in China by its partner, HanX Biopharmaceuticals. Hanx and Onconova established the research collaboration in 2017.

    What else is there for Onvonova?  The company anticipates filing for the investigational new drug (IND) application to evaluate ON 123300 in the United States in Q4 2020 for this program. We believe this will be…




    Click to get the full report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Release – Energy Fuels and Team from Penn State University Selected by U.S. Department of Energy

Energy Fuels & Team from Penn State University Selected by U.S. Department of Energy to Develop Design for the Production of Rare Earth Elements from Coal-Based Resources

 

LAKEWOOD, Colo., Sept. 21, 2020 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that it has been advised by the U.S. Department of Energy (“DOE”) Office of Fossil Energy (“FE”) and the National Energy Technology Laboratory (“NETL”) of their intent to award a contract to Energy Fuels, working with a team from Penn State, to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides (“REO”) from coal-based resources in an environmentally benign fashion. Furthermore, the DOE has the option to award Energy Fuels a contract for the completion of a feasibility study on this initiative.

The DOE has already demonstrated the technical feasibility of extracting rare earth elements (“REE”) from coal and coal-based resources, including coal refuse, over/under burden materials, power generation ash and the like. The DOE wishes to accelerate the advancement of commercially viable technologies to produce rare earth elements from these coal-based resources. Energy Fuels applied for this grant in June 2020, as REEs contained in these coal-based resources are similar to the REEs contained in other materials the Company is currently evaluating in its REE program.

The first phase of DOE funding will allow Energy Fuels and the team from Penn State to complete a detailed conceptual design and flowsheet for the potential commercial operation of a facility that produces REOs from coal-based resources. Following this phase, the DOE will conduct a merit evaluation and determine whether to award the funding for the development of a feasibility study.

Mark S. Chalmers, President and CEO of Energy Fuels stated: “We are excited to have the opportunity to work with the DOE office of Fossil Energy, the National Energy Technology Laboratory, and Penn State on this important rare earth initiative. Energy Fuels has been carrying out substantial work over the past year to explore the potential for implementing a commercial rare earth recovery and processing program at our White Mesa Mill. This initiative to produce REOs from coal-based resources is complementary to our ongoing efforts and will potentially broaden the sources of REE feedstock available to us in the future. We also hope this project opens the door for us to work with the the DOE and other agencies on future rare earth initiatives.

“Rare earths are used in a host of advanced and everyday technologies, including cell phones, computers, renewable energy generation, batteries, automobiles, and military applications. However, the U.S. does not currently have a fully integrated rare earth supply chain. Therefore, the government has made it a priority to assist in the development of domestic sources of rare earth production. With this award, we are excited to play a role in this effort, while also pursuing our other complementary rare earth initiatives.”

 

About Energy Fuels: Energy Fuels is a leading US-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the potential to implement a commercial rare earth recovery and processing program at its White Mesa Mill. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers, the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU”, and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

 

Cautionary Notes: This news release contains certain “Forward Looking Information” and “Forward Looking Statements” within the meaning of applicable United States and Canadian securities legislation, which may include, but is not limited to, statements with respect to: any expectation that DOE will in fact award a contract to Energy Fuels to evaluate and develop a conceptual design to allow for the commercial production of mixed REOs from coal-based resources, as advised by DOE; any expectation that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative; any expectation that this initiative may be complementary to Energy Fuels’ ongoing efforts or will potentially broaden the sources of REO feedstock available to Energy Fuels in the future; any expectation that this project may open the door for Energy Fuels to work with the DOE and other agencies on future rare earth initiatives, or that Energy Fuels may play a substantial role in the U.S. government’s priority to assist in the development of domestic sources of rare earth production; and any expectation regarding the ability of Energy Fuels to implement a commercial rare earth recovery and processing program. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects,” “does not expect,” “is expected,” “is likely,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “does not anticipate,” or “believes,” or variations of such words and phrases, or state that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” “be achieved” or “have the potential to.” All statements, other than statements of historical fact, herein are considered to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements express or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: any expectation that DOE will in fact award a contract to Energy Fuels to evaluate and develop a conceptual design to allow for the commercial production of mixed REOs from coal-based resources, as advised by DOE; any expectation that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative; any expectation that this initiative may be complementary to Energy Fuels’ ongoing efforts or will potentially broaden the sources of REO feedstock available to Energy Fuels in the future; any expectation that this project may open the door for Energy Fuels to work with the DOE and other agencies on future rare earth initiatives, or that Energy Fuels may play a substantial role in the U.S. government’s priority to assist in the development of domestic sources of rare earth production; any expectation regarding the ability of Energy Fuels to implement a commercial rare earth recovery and processing program; and the other factors described under the caption “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K, which is available for review on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com, and on the Company’s website at www.energyfuels.com. Forward-looking statements contained herein are made as of the date of this news release, and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. The Company assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Energy Fuels Inc., Curtis Moore – VP – Marketing & Corporate Development, (303) 974-2140 or Toll free: (888) 864-2125, investorinfo@energyfuels.com, www.energyfuels.com

Onconova Therapeutics (ONTX) – CDK4/6 Program Advances into Clinic in China

Monday, September 21, 2020

Onconova Therapeutics Inc. (ONTX)

CDK4/6 Program Advances into Clinic in China

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Trial initiation in China by research partner Hanx. Onconova announced the commencement of trial of its CDK4/6 and ARK5 inhibitor ON 123300 in China by its partner, HanX Biopharmaceuticals. Hanx and Onconova established the research collaboration in 2017.

    What else is there for Onvonova?  The company anticipates filing for the investigational new drug (IND) application to evaluate ON 123300 in the United States in Q4 2020 for this program. We believe this will be…




    Click to get the full report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

U.S. Debt as a Percentage of GDP Skyrocketing. Should We Be Concerned?

 

U.S. Debt as a Percentage of GDP Has Hit Levels Not Seen Since World War II

 

The federal budget deficit is projected to hit a record $3.3 trillion due, in part, to government expenditures to fight the coronavirus.  With the deficit, the U.S. national debt is now more than $26 trillion.  With the U.S. annual gross domestic product dropping to $19.5 billion in the second quarter, that means that debt as a percentage of GDP has skyrocketed to 133%, up from a level of 106% in 2019.  The table below shows that the debt/GDP number has grown steadily over the last forty years, with big jumps coming during periods when the government has stimulated the economy.  In 2009, for example, debt/GDP jumped from 68% to 83% when the government bailed out distressed financial institutions.  Increased government spending during times of economic weakness is an unfortunate necessity.  More alarming, however, is the fact that debt/GDP percentage is not reduced during times of prosperity.  

 

 

How much debt is too much debt?  Even before accounting for this year’s stimulus spending, the United States was responsible for 31% of the world’s debt.  Presumedly, that debt must be repaid at some point. At current levels, the U.S. debt represents approximately $80,000 for every man, woman, and child living in the United States. Is the current level of debt placing a burden on future generations? Or should debt be viewed as a cheap form of financing that should be used as long as it does not lead to higher inflation?  This article explores the pluses and minuses of higher government debt levels.

 

 

Rising debt is a big issue

  • The government is saddling future generations
    with debt
    .  If one assumes that debt must be repaid, GDP is one measure of a country’s ability to repay its debt.  Think of debt to GDP as a measurement akin to debt to sales for corporations.  When debt was only 30% of GDP as recently as thirty years ago, it was reasonable to believe that the country could repay its debt in the foreseeable future.  With debt levels at 130% of GDP and approaching 150%, such repayment is harder to imagine without future generations taking severe austerity measures.
  • High debt levels choke out savings needed to
    fund corporate borrowing.
      The government must borrow the debt from someone.  In theory, that means that there are fewer dollars to purchase corporate bonds, and corporations must offer higher interest rates to bond investors.  This could affect corporate profitability and the ability to fund investments needed to fuel growth.
  • Higher debt limits the government’s ability
    to stimulate the economy in the future
    .  No one questions whether governments should borrow to stimulate the economy during times of economic weakness.  However, it can not do so forever.  Debt cannot rise without limit.  Therefore, increasing debt levels means that the government will be less able to do so in the future should the need arise.
  • On-balance-sheet debt does not include many
    other government obligations.
      The national debt reflects the cumulation of annual federal budget deficits.  However, there are many other government obligations.  Social Security is an example of a government obligation not included in federal debt.  Economist Jim Hamilton estimates that off-balance-sheet liabilities could exceed $70 trillion, or roughly three times that of on-balance-sheet debt.
  • Our debt is held by foreign governments and
    carries the risk of being used against us for political reasons.
    Foreign entities own $6 trillion, or 29%, of the debt issued by the U.S. government, including $1 trillion held by China.  Should a country make a sudden decision to sell U.S. Treasuries, it could have negative implications for treasury market and the U.S. economy.  The large ownership by foreign entities is the result of the fact that the United States has run a trade deficit for many decades.  If a foreign entity were to suddenly decide that it no longer wanted to hold U.S. dollars in the form of treasuries, it could cause the dollar to drop suddenly and weaken the nation’s purchasing power.
  • A loss of confidence in the government’s
    ability to repay debt could be disastrous.
      Treasury rates are low because the bonds are backed by the full faith and credit of the U.S. government.  But what if investors begin to doubt the country’s ability or willingness to pay back their debts?  Such doubt could lead to a wave of selling in the treasury markets, pushing interest rates higher and thus putting additional pressures on the government.

 

 

Rising debt is not a big issue

  • Other countries have a higher debt to GDP
    rate
    .  The United States is not alone in reporting rising debt levels. Other countries such as Japan and Greece have spent their way towards economic growth and are doing well.  Japan’s debt, for example, is 235% of its GDP.
  • The nation has had debt levels larger than
    GDP before and survived.
    As mentioned earlier, the U.S. debt as percentage of GDP rose above 100% during World War II due to increased government spending. When that spending stopped, debt levels decreased.  Government stimulus to combat the effects of the pandemic can be viewed as a temporary increase in spending.  There is no reason to believe debt spending will resume to more normal levels once the impacts of the virus subside.
  • Not borrowing to stimulate the economy would
    mean lower GDP, so the rate would rise anyways
    . Federal deficits are the function of two things: government spending and the receipt of taxes.  Since taxes are directly correlated to GDP, government spending to stimulate GDP growth can be viewed as an investment that will result in higher tax collection.  Conversely, if the government were to not spend money to grow the economy, the debt-to-GDP ratio could rise anyway because of negative or limited GDP growth.
  • Interest rates are low. The United States is engaging in a strategy of increasing debt while at the same time lowering interest rates through moral suasion.  The strategy of increasing debt while pushing interest rates lower is a key component of Modern Monetary Theory. The Fed has set the discount rate (the rate at which eligible financial institutions may borrow funds) at the low rate of 0.25%.  This directly affects the rate at which financial institutions lend to customers.  To date, there is no sign that government borrowing is affecting corporate borrowing.

 

Conclusion

The debate about government debt levels will probably continue for centuries.  To date, rising debt levels have not had an adverse effect on interest rates, inflation, or corporate lending.  On the other hand, the U.S is approaching debt levels never seen before in history.  In April, the Congressional Budget Office projected the deficit for Fiscal Year 2020 will be $3.7 trillion.  If another stimulus package is passed, the deficit could read $5 trillion. The CBO also projects fiscal 2021 government spending of $4.8 trillion.  That means that the government will borrow more in 2020 than it typically will spend in a given year.  Repaying the debt cannot be done by cutting government spending for a few years. It will take decades of austerity. 

 

Suggested Reading:

JOLTS Report Suggests More Risk Taking

Small-cap Stocks are Looking Better for Investors

Can One Do Well and Do Good in Tandem

 

Each event in our popular Virtual Road Shows Series has a maximum capacity of 100 online investors. To take part, listen to and perhaps get your questions answered, see which virtual investor meeting intrigues you 
here.

 

Sources:

https://www.cnbc.com/2020/09/02/budget-deficit-to-hit-record-3point3-trillion-due-to-virus-recession.html, CNBC, September 9, 2020

https://theconversation.com/why-the-22-trillion-national-debt-doesnt-matter-heres-what-you-should-worry-about-instead-111805, The Conversation, February 14, 2019

https://www.investopedia.com/articles/investing/080615/china-owns-us-debt-how-much.asp, Investopedia, January 15, 2020

 

Small-cap Stocks are Looking Better for Investors

 

Small-Cap Stocks Have Shifted into Outperformance Mode

 

The behavior of drivers I witnessed while driving south from New York to Florida after Labor Day reminded me of reactions prevalent among market participants. Behaviors that literally drive travelers; from the professional (truck driver) to the guy in the sports car, or the family cruising in the SUV, also impact investor behaviors. There are people in the markets and on the road,  especially professionals, that always seem to know things first and how to respond. There are also impatient drivers and investors, those that want fast results, and safer people just trying to be prudent. They’re all on the same road, but their level of expertise and reason for being there is different, so is their ability to change when needed.

My personal driving style is risk-averse; I just want to arrive alive. My normal pace is about 7 miles per hour above the posted speed limit. This is often a little slower than those around me, but not so slow as to annoy others on the road. During this most recent road trip, while just south of  Annapolis, there was a significant number of cars on the road, yet the pace was brisk. We were all making good headway (just as investors in large-cap, especially tech, have over most of the summer had been). Like these investors, I let my guard down with everyone else who had grown comfortable with the velocity that we were moving. I was startled from my comfort when a car came past exceeding the average speed by 15-20 mph. I then noticed that a few of the cars around me increased their own pace.  People are inclined to increase their risky behavior when they see others less cautious and benefitting from it. As far as I can tell, the truck drivers didn’t change their behavior.  As professionals, they learned from experience and training what was best for them. A few miles past where the cars sped up, I saw a number of vehicles, mainly trucks exiting the interstate. This got my attention, and I considered doing the same as these drivers are often more in the know than the occasional vacationer like myself. Without a known alternative route to take me where I wanted to go, I decided not to.

It did not take long before I realized why the professional drivers exited. The car that startled me as it raced past earlier had just gotten into an accident. It was left overturned with steam coming from what I assume was the front.  The cars around me quickly slowed their pace to the speed limit. I reduced my speed as well; I also lowered the volume on my music and placed my hands firmly at 10 & 2 o’clock on the steering wheel. Seeing what could happen caused us all to be safer drivers. For some of us, that lasted about ten miles. After that I saw people begin to resume their speed. For others, they shook off the reality of the possibility of crashing sooner and resumed their pace quickly. This wreck wasn’t the only one I witnessed on my 1200-mile drive. Each time I saw caution temporarily increase among those around me. The stock market has behaved the same way throughout 2020. On two occasions we’ve experienced severe and sudden downturns; after each, people have quickly resumed their pace.

Stock Market Highway

Leading up to the late February 2020 record-level highs in the major indexes, we saw many investors speeding into the market. Tech stocks were especially popular, but many sectors had continued strength as we ignored warnings of an overextended market, sorted out pandemic risks, and the idea that the pace may be dangerous. The markets did come screeching to a halt after President’s Day  as some participants exited out of equities and others took alternative routes to stocks most likely to benefit from a response to the pandemic.

The 30% crash ending in March caused many to head to the sidelines as the reality of what could happen became reality. Some of these investors stayed cautious and missed opportunities as the market rose again. Others pivoted to companies that eventually proved to be the darlings of the situation. This included big tech, pharmaceuticals, and online retail.

 

Source TradingView.com – NASDAQ 100 E-Mini as Proxy for NASDAQ 100 Stocks (1 year)

In the past few weeks, these darlings, the companies that had been speeding the most after the earlier crash, have hit another rough patch. During the last 14 days (Since September 4) the NASDAQ 100 is down 5.9% as investors move money out and find different avenues.

Taking an Exit

On September 2, thanks to tech stocks and other COVID related plays, the large-cap indexes had reached a new all-time high. In the short time since then, they have given up more than 10% (NASDAQ 100). Although this rapid selloff is not currently as large as the 30% route in March, it was rapid and exceeds the psychological 10% level that investors react to.

The question now is, is this a pause before large tech investors begin “bargain” hunting, or have they shifted their focus. Chart comparisons for popular indexes may be able to answer this. If the pattern holds, it looks like investors may have exited the large-cap tech highway and found an alternative route in small-cap investments. This is starting to become visible when comparing major index results over the past 14 days, and money flows among ETFs.

While the three most quoted large-cap indices are down over the past two weeks, the small-cap stocks, which weren’t getting much attention during the race to the new peak, have significantly outperformed as money was taken off the table in the high flying large caps and placed instead in companies with lower market caps. This may prove to be a smart detour as the economy gets on a stronger footing.

 

 

From Friday, September 4 through Friday, September 18, the Russell 2000 index showed positive results while the DOW 30, S&P 500, and NASDAQ 100 were down meaningfully.

 

 

Fund flows into ETFs with performance that tracks small-cap indices have outpaced flows into large-cap funds. This change suggests that market participants selling out of large-cap have not left the market. They have just adjusted the road they believe is now safer and could offer a better return.

 

Shifting Gears

The small-cap companies represented in the Russell 2000 rely less on profits from doing business overseas than the large-cap indexes. As the U.S. pace of recovery is strong, it makes sense to look domestically for value. Larger corporations with stable and stronger financials were the “flight-to-quality” trade early in the pandemic. Unwinding these trades also has the effect of cash moving back into a more diversified position.  Domestic small-caps also have less international exposure, they are more shielded from sovereign and other geopolitical risks. The U.S. relationship with China, Brexit concerns, and a Presidential election may complicate global investing. This bodes well for companies that primarily have their operations in North America.

Though far from the “best-ever” economic levels we saw pre-pandemic, data has been improving. The unemployment rate is at 8.4%, this is much better than what many economists had forecasted for the remainder of the year, manufacturing has also expanded, and confidence is high

Take-Away

The relative increase in small-cap stock interes shows that investors think the run-up in companies that benefit from social distancing are low on gas.

Small-cap stocks are providing somewhat of a refuge from the rout that tore through equity markets this month. This signals that investors see brighter days ahead for the economy as pandemic lockdowns are lifted.

Not unlike highway driving, market movement is the cumulative effects of all the behaviors of those involved. It makes sense that there are some investors who have already begun leaving the large-cap companies that had treated them well and are now taking other routes. The conditions are changing, it may be time for investors to take it off autopilot and adjust once again for what may be called for.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading:

Do Analyst Price Targets Matter?

Fear of Missing the Next Apple

A Virtually Perfect Time to be in This Business

 

Enjoy Premium Channelchek Content at No Cost

 

Each event in our popular Virtual Road Shows Series has a maximum capacity of 100 online investors. To take part, listen to and perhaps get your questions answered, see which virtual investor meeting intrigues you here.

 

Sources:

Nasdaq, tech stocks coming out of correction

Small Caps Emerge Relatively Unscathed in Megatech Bludgeoning

ETF.com

 

Notch Pathway Activation and Severe Cancers

 

The Roles of Notch Pathways and Notch Signaling in Cancers

 

Notch signaling regulates a diverse array of functions in the hematopoietic system and other tissues, including lineage commitment, differentiation, cell cycle progression, and maintenance and self-renewal of stem cells. The Notch receptor was first identified by Thomas Hunt Morgan in 1917 with the observation of a Drosophila strain, then cloned by Spyros Artavanis-Tsakonas and Michael Young decades later in 1980. Notch plays an important role in many types of cancer, particularly in the regulation of stem and progenitor cells.

The effect of Notch signaling is highly context-dependent. It is capable of acting as an oncogene or tumor-suppressor gene dependent on the presence of other genetic lesions and other factors. Multiple mutations in Notch genes are identified in a broad spectrum of cancers. They reflect various roles for Notch in different cancer contexts. Remarkably, functional studies implicate the importance of Notch signaling in all of the hallmarks of cancer (Exhibit 1), roles that range from oncogenic to tumor suppressive depending on cancer type.

 

Exhibit 1. Cancer hallmarks potentially in?uenced by Notch signaling. Positive (oncogenic) effects (green) and tumor-suppressive effects (red) are shown.

 Notes: ACC, adenoid cystic carcinoma; breast Ca, breast carcinoma; CLL, chronic lymphocytic leukemia; SCCa, squamous cell carcinoma; T-ALL, T cell acute lymphoblastic leukemia; TIC, tumor-initiating cell.

Source: Annu. Rev. Pathol. Mech. Dis. 2017. 12:245–75

 

Notch pathway activation has been implicated in cancer (solid tumor and hematological cancers) and associated with more aggressive cancers. Gamma secretase is a protease (a type enzyme) complex responsible for Notch activation via cleavage of numerous transmembrane proteins, including amyloid precursor protein (APP), Notch, HER4, E-cadherin, N-cadherin, BCMA, and CD44. These substrates have been associated with a variety of diseases, including cancer and Alzheimer’s diseases. Hence, these provide a foundation and rationale for evaluating gamma-secretase and Notch as a therapeutic target.

 

Exhibit 2. Notch signaling and strategies for pharmacological targeting of this pathway

Source: Moore G. et al. Cells 2020, 9, 1503

 

There are numerous strategies to pharmacologically target Notch signaling, including Notch receptor monoclonal antibodies, ligand-targeted antibodies (e.g., DLL-4 antibodies), gamma-secretase inhibitors (GSIs), and Notch transcript complex small molecules. Among the multiple gamma-secretase/Notch inhibitors:

  • Ayala Pharmaceuticals (AYLA)’ pan-Notch/gamma-secretase inhibitor AL101 is being assessed in an open-label Phase 2 clinical trial (Accuracy) for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations.
  • SpringWorks Therapeutics (SWTX)’ gamma-secretase inhibitor nirogacestat is evaluated in a registrational Phase 3 (DeFi) clinical trial for the treatment of desmoid tumors.
  • Cellestia Biotech (Private)’s pan-Notch inhibitor CB-103 is evaluated in a Phase 1/2A study in adult patients (pts) with advanced or metastatic solid tumors and hematological malignancies characterized by alterations of the Notch signaling, including breast cancer, colorectal cancer, cholangiocellular carcinoma, sarcoma, desmoid tumor, adenoid cystic carcinoma, non-Hodgkin lymphoma, and malignant glomus tumor.

 

Suggested Content:

Genprex Virtual Roadshow (Video)

PDS Biotechnology C-Suite Interview (Video)

Neovasc C-Suite Interview (Video)

 

Subscribe to Channelchek’s YouTube Channel

 

Photo: Cancer Cells

Release – Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

 

LIANYUNGANG, CHINA & JUPITER, FL / ACCESSWIRE / August 17, 2020 Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. (“Hengrui”) (SSE:600276) to apply Dyadic’s C1 technology to the development of selected Hengrui biologic drug(s).

“We are very excited to partner with Hengrui, one of the most innovative and inventive global biopharmaceutical companies. This collaboration also highlights the appeal of C1’s value proposition, producing cell lines at higher expression levels and lower cost, to address global demand for more efficient biomanufacturing processes of biologic vaccines and drugs. We are looking forward to a successful collaboration with Hengrui,” said Dyadic’s CEO, Mark Emalfarb.

Dr. Lianshan Zhang, Hengrui’s R&D President, commented, “We are interested in Dyadic’s C1 technology, which has potential to help us produce biotherapeutics in a more cost-effective fashion. As a result, we are leveraging our combined expertise and working closely with Dyadic as we share their vision of creating biomedicines to benefit patients globally.”

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, Hengrui has 6 new molecular entities approved in China as well as 30 plus programs in clinical development in China, US, EU and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, Hengrui is committed to bringing high quality products to patients. For more information, please visit http://www.hrs.com.cn/index.html.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at http://www.dyadic.com.

Contact:

Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com

 

Lineage Cell Therapeutics (LCTX) – Initiating Coverage, Eye of Stem Cell Treatments and Beyond

Thursday, September 17, 2020

Lineage Cell Therapeutics (LCTX)

Initiating Coverage, Eye of Stem Cell Treatments and Beyond

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer and in preclinical development for additional cancers and as a vaccine against infectious diseases, including SARS-CoV-2, the virus which causes COVID-19. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Topline. We like how strategic and forward-looking Lineage has been recently with its pipeline programs. The management team implemented multiple changes in the corporate structure including the acquisition of Asterias Biotherapeutics – prepended two additional cell therapy product candidates, OPC1 and VAC2 in its pipeline. We believe that the value-driving components of the pipeline have been in flux and have not been on investors’ radar. Our analyses show that out of the pipeline, OpRegen and VAC2 may be subject to the largest near and medium-term value inflections which could be transformational for the company and its investors.

    The What.  In this report, we highlight the company’s innovative cell therapy pipeline as it begins to yield data. The lead program, OpRegen, is the largest contributor to our valuation with >$0.5B projected sales at peak in the age-related macular degeneration (AMD) market, which is expected to reach $18.7B sales in 2028. The second lead asset, OPC1, is in a small market of acute spinal cord …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Low Bids Become Awards of $119 million. More Awards Ahead

Thursday, September 17, 2020

Great Lakes Dredge & Dock (GLDD)

Low Bids Become Awards of $119 million. More Awards Ahead.

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The company only’s operating segments is Dredging. Dredging involves the enhancement or preservation of navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand or rock. Its projects portfolio includes Coastal Restoration, Coastal Protection, Port expansion, and others.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Low bids converted into final awards of $118.8 million. A $4.3 million award was added after market closed so low bids pending award of $33.6 million remain outstanding. Yesterday, final awards of $118.8 million were announced, including several projects that we highlighted as pending at the start of the week. The awarded work includes capital work of $75.6 million, coastal protection work of $37.0 million and maintenance work of $6.2 million. The two largest projects in Charleston and Freeport represented ~$68.4 million of our low apparent bid estimate, but several low bids on other projects were not included and are pending award. The Fernandina Harbor award of $4.3 million was finalized late yesterday so we consequently estimate that low apparent bids of $33.6 million remain outstanding.

    Combined with awards announced in mid-August that totaled ~$118 million, the new awards of $119 million and low bids pending award of $38 million should help stabilize backlog in 3Q2020.  In 3Q2020, awards of $237 million have been announced, including $119 million announced yesterday and $118 million announced in mid-August. The scope of work is broad and it includes a total of six projects …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Vectrus (VEC) – New Contract Award

Wednesday, September 16, 2020

Vectrus (VEC)

New Contract Award

Vectrus Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offer facility and logistics services and information technology and network communications services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations and others.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Award. On Monday, the DoD announced Vectrus has been awarded a $43.4 million ID/IQ contract for base operations support services at Naval Station Guantanamo Bay. The maximum dollar value including the base period and four option years is $196.1 million. Back in 2018, Vectrus had been awarded a two-year $60 million contract for these services.

    And Extension.  On August 27th, Vectrus was awarded an $116.8 million modification to its OMDAC-SWACA contract for continued support of critical operation, maintenance and defense of Army communications, which supports the Army Operational Base Communications Information Systems and infrastructure in support of U.S. Central Command forces. The extension is through February 28, 2021, although a new …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.